RTP Mobile Logo
Year in Review — Proceedings from a Multitumor CME Symposium Focused on Key Clinical Presentations and Papers in Oncology
Released December 2012

Proceedings from a daylong symposium featuring key clinical presentations and papers in breast, lung, gastrointestinal, genitourinary, skin and select hematologic cancers. Including perspectives from Drs Daniel G Haller, Hagop M Kantarjian, Corey J Langer, Karl Lewis, Sagar Lonial, Kathy D Miller, Bert H O’Neil and David I Quinn. (Video program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE

    This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows and other oncology healthcare professionals.

    OVERVIEW OF ACTIVITY

    Each year countless data sets related to the management of common cancers are released to the oncology community via presentation at cancer conferences and publication in peer-reviewed journals. This massive outpouring of information has enormous positive benefits for the cancer community, but the truth is it also creates a major challenge for practicing oncologists and hematologists. To bridge the gap between research and patient care, this web-based activity uses a mix of didactic presentations and moderated case-based discussion to apply evidence-based concepts in routine clinical care. The activity focuses on 6 different areas of oncology: breast, lung, gastrointestinal, genitourinary, skin and select hematologic cancers.
     
    These have been selected based on a number of factors, including the overwhelming need for and interest of practicing oncologists in additional educational resources in these areas. By providing access to the latest research developments across these cancer types, this activity will assist medical oncologists, hematologists, hematology-oncology fellows and other oncology healthcare professionals in the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES
    • Effectively apply the results of practice-changing clinical research to the care of patients with breast, lung, gastrointestinal, genitourinary, skin and select hematologic cancers.
    • Compare and contrast the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
    • Recall ongoing trials in breast, lung, gastrointestinal, genitourinary, skin and select hematologic cancers, and refer appropriate patients for study participation.
    • Utilize an understanding of tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
    • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT

    Research To Practice designates this enduring material for a maximum of 6.75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    HOW TO USE THIS CME ACTIVITY

    This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 70% or better and fill out the Educational Assessment and Credit Form located on our website at ResearchToPractice.com/YiRMultitumor12/CME.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Daniel G Haller, MD
    Professor of Medicine Emeritus
    Abramson Cancer Center of the University of Pennsylvania
    Perelman School of Medicine at the University of Pennsylvania
    Philadelphia, Pennsylvania

    Advisory Committee: Genentech BioOncology, Novartis Pharmaceuticals Corporation, Sanofi; Consulting Agreements: Genomic Health Inc, Novartis Pharmaceuticals Corporation; Independent Data Monitoring Committee: ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company.

    Hagop M Kantarjian, MD
    Chairman and Professor, Leukemia Department
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Paid Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi.

    Corey J Langer, MD
    Director of Thoracic Oncology
    Abramson Cancer Center
    Professor of Medicine
    University of Pennsylvania
    Vice Chair, Radiation Therapy Oncology Group
    Philadelphia, Pennsylvania

    Advisory Committee: Abbott Laboratories, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, EMD Serono Inc, Genentech BioOncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Novartis Pharmaceuticals Corporation, Synta Pharmaceuticals Corp; Consulting Agreements: Abbott Laboratories, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Synta Pharmaceuticals Corp; Data and Safety Monitoring Committee: Amgen Inc; Paid Research: Daiichi Sankyo Inc, EMD Serono Inc, Genentech BioOncology, GlaxoSmithKline.

    Karl Lewis, MD
    Associate Professor of Medicine
    Division of Medical Oncology
    Associate Director of the Melanoma Research Clinics
    University of Colorado Denver
    Aurora, Colorado

    Advisory Committee and Consulting Agreement: Genentech BioOncology; Paid Research: Genentech BioOncology, Novartis Pharmaceuticals Corporation.

    Sagar Lonial, MD
    Professor
    Vice Chair of Clinical Affairs
    Director of Translational Research, B-Cell Malignancy Program
    Department of Hematology and Medical Oncology
    Winship Cancer Institute
    Emory University School of Medicine
    Atlanta, Georgia

    Advisory Committee and Consulting Agreements: Acetylon Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Merck and Company Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc.

    Kathy D Miller, MD
    Sheila D Ward Scholar of Medicine
    Associate Professor of Medicine
    The Indiana University Melvin and Bren Simon Cancer Center
    Indianapolis, Indiana

    Advisory Committee: Clovis Oncology, Genentech BioOncology; Clinical Trials: Geron, Merrimack Pharmaceuticals; Consulting Agreements: Bristol-Myers Squibb Company, Roche Laboratories Inc; Paid Research: Clovis Oncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company; Speakers Bureau: Genentech BioOncology, Roche Laboratories Inc.

    Bert H O’Neil, MD
    Associate Professor
    Director, GI Oncology Clinical Research Program
    Medical Director, UNC Cancer Clinical Trials Protocol Office 
    UNC Lineberger Comprehensive Cancer Center
    Chapel Hill, North Carolina

    Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Sanofi; Consulting Agreements: Abbott Laboratories, Genentech BioOncology; Data and Safety Monitoring Committee: GlaxoSmithKline; Speakers Bureau: Genomic Health Inc.

    David I Quinn, MBBS, PhD
    Medical Director, Norris Cancer Hospital and Clinics
    Leader, Developmental Therapeutics
    Head, GU Cancer Section
    Division of Cancer Medicine and Blood Diseases
    USC/Norris Comprehensive Cancer Center
    Los Angeles, California

    Advisory Committee: Algeta ASA, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Dendreon Corporation, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Pfizer Inc; Consulting Agreements: Amgen Inc, Dendreon Corporation, Medivation, Novartis Pharmaceuticals Corporation, Pfizer Inc.

    EDITOR
    Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Lilly USA LLC, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Regeneron Pharmaceuticals and Sanofi.

    Hardware/Software Requirements:

    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: December 2012
    Expiration date
    : December 2013

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WiFi is recommended for best performance):

Module 1:
Multiple Myeloma
Sagar Lonial, MD
Module 2:
Dermatologic Oncology
Karl Lewis, MD
Module 3:
Renal Cell Carcinoma and Prostate Cancer
David I Quinn, MBBS, PhD
Module 4:
Chronic Myeloid Leukemia and Myelofibrosis
Hagop M Kantarjian, MD
Module 5:
Colorectal Cancer
Daniel G Haller, MD
Module 6:
Noncolorectal GI Cancers
Bert H O'Neil, MD
Module 7:
Breast Cancer
Kathy D Miller, MD
Module 8:
Non-Small Cell Lung Cancer
Corey J Langer, MD